A Comparison of Morphine and Morphine Plus Dexmedetomidine in Chronic Cancer Pain

Cukurova University40 enrolled

Overview

The purpose of this study is to determine whether dexmedetomidine added to morphine is effective in the treatment of chronic cancer pain.

We conduct the study in Cukurova University Faculty of Medicine Research Hospital after obtaining ethics committee approval and patient's informed consent. Patients with cancer pain are allocated into two group to receive Patient Controlled Analgesia with morphine or morphine plus dexmedetomidine.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Chronic Pain

Interventions

MorphineDRUG

Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval

Morphine plus dexmedetomidineDRUG

Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval

Eligibility

Sex: ALLMin age: 20 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients with chronic cancer pain * between 20-80 years old age Exclusion Criteria: * the presence of severe systemic disease(cardiac, pulmonary, hepatic or renal) * psychiatric or neurologic disease * unable to communicate verbally * nausea and vomiting * patient's refusal

Locations (1)

Cukurova University Faculty of Medicine Research Hospital

Adana, Turkey (Türkiye)

Outcomes

Primary Outcomes

Morphine consumption (mg)

cumulative morphine consumption for 24 hours

Time frame: 24 hours

Secondary Outcomes

Pain score

visual analog scale to assess pain degree

Time frame: 24 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.